CME/CE Podcast: Using GLP-1 RAs to Reduce CV Risk in T2D

10/13/23 • 13 min

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/using-glp-1-ras-to-reduce-cv-risk-in-t2d-9134
Summary
Type 2 diabetes (T2D) doubles a patient’s risk for atherosclerotic cardiovascular disease (ASCVD), which is the leading cause of morbidity and mortality in patients with T2D. The 2023 ADA guidelines now recommend consideration of GLP-1 RAs in patients with T2D and ASCVD or indicators of ASCVD risk, independently of A1C and metformin use. In this episode, Dr. Pam Taub reviews recent updates in the cardiovascular benefits and appropriate use of GLP-1 receptor agonists for managing patients with T2D.
Learning Objectives

Incorporate early use of GLP-1 RA therapy in appropriate patients with T2D using a holistic approach, considering administration route and optimal dosing
Overcome barriers to GLP-1 RA uptake and medication adherence in T2D through patient counseling to manage adverse effects

This activity is accredited for CME/CE Credit
Association of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Association of Black Cardiologists, Inc. (ABC) designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, contact NACE at [email protected].
Summary of Individual Disclosures
Dr. Taub financial relationships:
Consultant: Amgen, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Esperion, Merck, Sanofi, Medtronic
Contracted Research: Amgen, Novartis
All her disclosures are related to cardiology
Dr. Morris financial relationships:
Consultant and advisor: Acorai, Regeneron, Merck
Speaker: Abbott, BI Lilly, Cytokinetics, Edwards Lifesciences, Ionis
Contracted Research: Boston Scientific, Cytokinetics, Ionis, Merck, Myokardia, Novartis
Stocks: Gilead Sciences
All her disclosures are related to heart failure.
All of the relevant financial relationships listed for these individuals have been mitigated.
Association of Black Cardiologists Planning Committee
Tierra Dillenburg has no relevant conflicts of interest with any ACCME-defined commercial interest.
Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Disclosure of Commercial Support
This educational activity is supported by an independent educational grant from Novo Nordisk Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Incorporate early use of GLP-1 RA therapy in appropriate patients with T2D using a holistic approach, considering administration route and optimal dosing
Overcome barriers to GLP-1 RA uptake and medication adherence in T2D through patient counseling to manage adverse effects

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Previous Episode

The APAPP Podcast Ep. 7: What’s new in Pulmonary Hypertension in 2023

Show Notes
NACE is excited to provide you with this podcast episode from our educational collaborator, The Association of Pulmonary Advanced Practice Providers (APAPP). APAPP is the first association of Advanced Practice Providers (APPs), both Nurse Practitioners and Physician Assistants, who work in the field of pulmonary medicine. APAPP's mission is to work together for the advancement of the profession and for the well-being of patients with pulmonary diseases. To learn more about APAPP and to get involved, please visit https://www.pulmapp.com.

Guest
Martha Kingman, FNP-C, DNP
Family Nurse Practitioner in the pulmonary hypertension clinic at the University of Texas Southwestern Medical Center at Dallas.
She is presently serving as sub-investigator in numerous ongoing pulmonary hypertension clinical trials. She is a member of the speakers’ bureaus for Actelion, United Therapeutics, and Gilead, and she gives her time and expertise to several nursing advisory boards. Martha is an active member of the PH Professional Network, having previously served on the national conference planning committee, and she has chaired the Research and Publications Committee of the Pulmonary Hypertension Association. She currently serves on the Editorial Board of Advances in Pulmonary Hypertension, the PHA’s journal.
Dr. Kingman earned a bachelor’s degree from Tulsa University School of Nursing in Tulsa, following which she worked in emergency department settings as a staff nurse and then as director of the ED after which she obtained her Master of Science in Nursing degree from Texas Woman’s University in Dallas. When she became board certified as a Family Nurse Practitioner, she accepted the job of nurse practitioner in the pulmonary department at UTSW Medical Center and remains in that role today. The majority of her clinical work involves the follow-up outpatient care of a large group of pulmonary hypertension patients at UTSW Medical Center. In May 2011, Dr. Kingman obtained her Doctorate in Nursing Practice from Texas Christian University.
Martha has published in the area of pulmonary hypertension and has spoken at local and national conferences. Her main area of research interest involves the safety of intravenous prostacyclins in the hospital setting.
Host
Corinne R. Young, MSN, FNP-C, FCCP
Director of APP and Clinical Services, Colorado Springs Pulmonary Consultants
President, APAPP, Colorado Springs, CO
Corinne Young is a Nurse Practitioner began working in the area of pulmonary disease in California in 2005. Since 2011, she has worked in a private pulmonary practice in Colorado Springs, Colorado. Involvement and the representation of advanced practice providers in the pulmonary world has been an important priority for Corinne. To that end, Corinne is the Founder and President of the Association of Pulmonary Advanced Practice Providers.

In addition to her work with APAPP, Corinne is currently one of ten NPs nationwide to become a Fellow of the American College of Chest Physicians. She works closely with the American College of Chest Physicians CHEST programs, and serves on the Interprofessional Team Network, Clinical Research Network, and on the Executive Programing Committee. Additionally, Corinne serves on the American Board of Internal Medicine Pulmonary Disease Board.

This Podcast episode does not offer CME/CE Credit.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Next Episode

The APAPP Podcast Ep. 8: ECMO: Who are the right patients

Guest
Susan Wilxon, MD
Dr. Susan Wilcox, M.D., attended medical school at Washington University School of Medicine and trained in Emergency Medicine in the Harvard Affiliated Emergency Medicine Residency, graduating in 2008. After residency, she completed an Anesthesia Critical Care fellowship at Massachusetts General Hospital. Since finishing her training in 2009, she divided her time between the Emergency Department and critical care, working in Surgical ICUs, Medical ICUs, and long-term vent units. In July 2017, she assumed the role of the Chief of the newly formed Division of Critical Care within the Department of Emergency Medicine MGH. In addition to attending in the Emergency Department, she also attends in the Heart Center ICU and serves as the Associate Chief Medical Officer of Boston MedFlight.
Host
Corinne R. Young, MSN, FNP-C, FCCP
Director of APP and Clinical Services, Colorado Springs Pulmonary Consultants
President, APAPP, Colorado Springs, CO
Corinne Young is a Nurse Practitioner began working in the area of pulmonary disease in California in 2005. Since 2011, she has worked in a private pulmonary practice in Colorado Springs, Colorado. Involvement and the representation of advanced practice providers in the pulmonary world has been an important priority for Corinne. To that end, Corinne is the Founder and President of the Association of Pulmonary Advanced Practice Providers.

In addition to her work with APAPP, Corinne is currently one of ten NPs nationwide to become a Fellow of the American College of Chest Physicians. She works closely with the American College of Chest Physicians CHEST programs, and serves on the Interprofessional Team Network, Clinical Research Network, and on the Executive Programing Committee. Additionally, Corinne serves on the American Board of Internal Medicine Pulmonary Disease Board.

This Podcast episode does not offer CME/CE Credit.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.